Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double blind, placebo controlled, multicenter, phase II study to
compare the anti-tumor activity as measured by progression-free survival (PFS) and the
tolerability of Sorafenib in combination with Dacarbazine (DTIC) versus DTIC in combination
with placebo in subjects with unresectable Stage III or Stage IV melanoma who have not
received prior cytotoxic chemotherapy. A total of approximately 98 subjects will be
randomized to receive DTIC + Sorafenib or DTIC + Placebo.